Does Alabama Medicaid Cover Wegovy or Zepbound? The Three PA Routes

No. As of November 2026, Alabama Medicaid does not cover Wegovy, Zepbound or any other GLP-1 for weight loss; its drug list calls both drugs “non-covered for weight reduction.”^[1] It does pay for three narrower uses with prior authorization: Zepbound for moderate to severe sleep apnea, and Wegovy to lower heart risk or to treat the liver disease MASH, in each case for adults who meet the state’s criteria.^[1][2]

Will Alabama Medicaid pay for a GLP-1 to lose weight?

It does not. The GLP-1 section of the state’s drug list carries two footnotes that settle the question. The Zepbound note rules out weight reduction “without OSA,” and the Wegovy note rules it out with no sleep apnea exception at all.^[1] The same footnotes appear on the January 2026 list, so this has been the rule all year.^[10]

Under federal law, every state may make that choice. Drugs used for weight loss sit on a short list of medicines a Medicaid program may leave out, alongside fertility and cosmetic drugs.^[5] Alabama uses the option for GLP-1s but not for every weight-loss drug, as the section on Xenical below shows. Our explainer on why Medicaid treats Ozempic and Wegovy differently covers the federal side in more depth.

When does Alabama Medicaid pay for a GLP-1?

In four situations. Type 2 diabetes is the broad one, and the other three are the uses the FDA has added to the Wegovy and Zepbound labels beyond weight.^[6][7] Since October 2026 the state groups those three under one heading in its instructions, “Incretin Mimetics for Non-Diabetes Indications.”^[2]

Two details in the instructions deserve a careful read. The sleep apnea and MASH bullets each say “no diagnosis of diabetes,” so a person with diabetes is steered to the diabetes route, where Mounjaro, the same drug as Zepbound, is already a preferred choice.^[1][2] The heart bullet in the October text does not repeat that phrase.^[2] And the MASH bullet leaves a door open below the usual weight line: a request with a BMI under 27 can still be considered with “appropriate documentation.”^[2]

What does Alabama require for Zepbound and sleep apnea?

Zepbound has an unusual standing here. It sits in the preferred column of Alabama’s list while Wegovy does not, but only for sleep apnea with obesity.^[1] The patient must be 18 or older, with sleep apnea rated moderate to severe, an AHI (apnea-hypopnea index) score from 15 up, and a BMI from 30 up.^[2] The prescriber also confirms that the patient has been counseled on diet and activity and is not on a second GLP-1.^[2]

What the instructions leave out matters as much. They set no CPAP trial and name no sleep specialist.^[2] That keeps Alabama close to the Zepbound label, whose sleep apnea use is limited to adults who also have obesity.^[6] Renewal is where sleep apnea differs from the other routes: instead of weight records, the prescriber can show better sleep, either on a sleepiness scale such as the Epworth or on a repeat sleep study.^[2] Our guide to Zepbound for sleep apnea explains the trials behind that indication.

Will Alabama Medicaid cover Wegovy for heart disease or fatty liver?

Yes, through prior authorization, although Wegovy is a non-preferred drug.^[1] For the heart route the request must document established cardiovascular disease in an adult with a BMI of 27 or more.^[2] That matches the label, which covers adults with heart disease and either obesity or overweight.^[7]

The MASH route covers adults with noncirrhotic disease and moderate to advanced fibrosis, stages F2 to F3, the same wording as the label.^[2][7] Alabama’s text asks for documentation that supports the diagnosis but, unlike some states, does not list a required test or a liver specialist.^[2] A biopsy report or a liver stiffness result still makes the strongest file. The FDA approved this use on an accelerated basis, and our page on GLP-1s and MASH covers what the trial showed.^[7]

How long does an approval last, and how do you renew it?

The first approval for any of the three non-diabetes uses lasts up to six months, and renewals can run up to 12 months.^[2] Heart and MASH renewals need weight records from the past 90 days showing adequate loss; sleep apnea renewals can use the sleep evidence described above instead.^[2] Diabetes approvals can run up to 12 months from the start.^[2]

How the request travels matters too. Diabetes drugs run through the state’s electronic prior authorization program, which can clear a claim from the pharmacy record, but the three non-diabetes uses are excluded from it and cannot be requested by phone.^[2] The prescriber files Form 369 with Acentra Health, the agency’s prior authorization contractor, by fax at 1-800-748-0116; the help line is 1-800-748-0130.^[2][3]

Does Alabama Medicaid cover any weight-loss drug?

One. Xenical (orlistat) has its own prior authorization criteria, starting at age 12, for a BMI of 27 or more with diabetes, high blood pressure or high cholesterol.^[2] The request must show at least six months of a physician-supervised diet and exercise program that did not work, and renewals need continued weight loss.^[2] Orlistat produces far smaller losses than a GLP-1; our review of orlistat and Alli sets out the evidence.

How do you appeal a denial in Alabama?

Start with the reason on the notice. A denial for missing paperwork, such as no sleep study or no BMI on file, is often fixed by resubmitting with the record. An appeal has little to argue if the only diagnosis is obesity, because no route exists for that.^[1]

For a formal appeal, Alabama’s rule requires the written fair hearing request to reach the agency within 60 days of the date the notice was mailed, and late requests are refused.^[4] Count from the mailing date on the notice, not the day it arrived. Our walkthrough of prior authorization and appeals covers what to put in the file, and the Alabama state page collects the same Medicaid facts in brief.

What can you do if Alabama Medicaid will not pay?

Cash is the main option, and the manufacturer copay cards will not help: Lilly’s savings card terms exclude anyone enrolled in Medicaid.^[8] Self-pay prices in the figures we track are $349 a month for most Wegovy pen doses through Novo Nordisk, and $299 at the starting dose, $399 at 5 mg and $449 at higher doses refilled on time for Lilly’s Zepbound KwikPen.^[8][9] Read each offer’s terms on government coverage before enrolling. Our list of the cheapest GLP-1 routes without insurance compares them.